The Innovative Medicines Initiative is successfully generating private funding and producing significant scientific output, an evaluation report has said.
Published 18 May, the evaluation reported on nine IMI projects completed by 2016, which spent a total of €217.6 million on pharmaceuticals R&D. For every €1 invested in the projects from the EU budget, an additional €1.64 was leveraged from industry, the report said.
The report stated that IMI projects have generated “vast amounts of new knowledge” because they have resulted in the publication of 546 scientific papers. Evidence of follow-on project suggests that IMI projects have had “some influence" on the R&D agenda in Europe, the report said
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.